@Biotech2k1 i’d be a little hesitant to give them too much credit there. That said they have done a good job with Zoryve getting it up to 400 run rate. similar to incyte JAK.
it’s just ~10x sales valuation with ~10 years of patent is a lot
@MurrayHillGuy1 don’t over think it. more likely a beautiful mid (or headed there) than anything else. Ex athletes likely to transform a bit in their 20s (for the better)
@Sanctuary_Bio@STL_Biotech FDA doesn’t care about investors. Nor should they.
I also think investors are blind to what FDA guidance received to biotechs really is vs how it is communicated publicly
@LifeSciVC@davidmaris@statnews don’t disagree but it is way easier to get an OTC device approved in EU. US doesn’t have that same pathway
saunders has also never been about fair prices